ADC Therapeutics SA (ADCT): Cost of Revenue
$5.80M
Year ended 2025-12-31
+20.7%
3-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.80M | -2.5% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $5.95M | +135.2% | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $2.53M | -23.4% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $3.30M | n/a | 2024-03-13, From 2022-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $5.80M | -2.5% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $37.21M | +138.5% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $42.79M | -7.2% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $29.70M | -5.1% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $57.56M | -31.5% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $20.92M | +0.2% |
| Nuvation Bio Inc. (NUVB) | 2024-12-31 | $7.08M | n/a |
| Journey Medical Corp (DERM) | 2025-12-31 | $20.92M | +0.2% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $12.45M | +40.2% |
Compare ADCT, ETON, LAB, SIGA side by side · Screen every company in Pharmaceutical Preparations ↗